Altering entry site preference of lentiviral vectors into neuronal cells by pseudotyping with envelope glycoproteins

Methods in Molecular Biology

Volumn 1382, Issue , 2016, Pages 175-186

  Kobayashi, Kenta ^a   Kato, Shigeki ^b   Inoue, Ken Ichi ^c   Takada, Masahiko ^c   Kobayashi, Kazuto ^b  

^a NATIONAL INSTITUTE FOR PHYSIOLOGICAL SCIENCES   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Entry site; Fusion glycoprotein; Gene transfer; Lentiviral vector; Neuron; Rabies virus glycoprotein; Retrograde transport; Vesicular stomatitis virus glycoprotein

Indexed keywords

LENTIVIRUS VECTOR; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

CELL BODY; DEGENERATIVE DISEASE; DENDRITE; NERVE CELL; NERVE ENDING; NEUROLOGIC DISEASE; NEUROTROPISM; NONHUMAN; PSEUDOTYPING; RABIES VIRUS; TRANSGENE; VESICULOVIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; LENTIVIRINAE; VIROLOGY; VIRUS ENTRY;

ANIMALS; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; LENTIVIRUS; NEURONS; TRANSDUCTION, GENETIC; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EID: 84948808177     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3271-9_12     Document Type: Chapter

References (72)

1. Azzouz M, Kingsman SM, Mazarakis ND (2004) Lentiviral vectors for treating and modeling human CNS disorders. J Gene Med 6:951–962
2. Wong LF, Goodhead L, Prat C et al (2006) Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications. Hum Gene Ther 17:1–9
3. Lundberg C, Björklund T, Carlsson T et al (2008) Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther 8:461–473
4. Kordower JH, Emborg ME, Bloch J et al (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science 290:767–773
5. Palfi S, Leventhal L, Chu Y et al (2002) Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci 22:4942–4954
6. Georgievska B, Jakobsson J, Persson E et al (2004) Regulated delivery of glial cell linederived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. Hum Gene Ther 15:934–944
7. Lo Bianco C, Schneider BL, Bauer M et al (2004) Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson’s disease. Proc Natl Acad Sci U S A 101:17510–17515
8. Fjord-Larsen L, Johansen JL, Kusk P et al (2005) Effi cient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modifi ed Neurturin construct. Exp Neurol 195:49–60
9. Vercammen L, Van der Perren A, Vaudano E et al (2006) Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson’s disease. Mol Ther 14: 716–723
10. McCoy MK, Ruhn KA, Martinez TN et al (2008) Intranigral lentiviral delivery of dominant- negative TNF attenuates neurodegeneration and behavioral defi cits in hemiparkinsonian rats. Mol Ther 16:1572–1579
11. Kafri T (2004) Gene delivery by lentivirus vectors an overview. Methods Mol Biol 246:367–390
12. Cockrell AS, Kafri T (2007) Gene delivery by lentivirus vectors. Mol Biotechnol 36: 184–204
13. Dull T, Zufferey R, Kelly M et al (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463–8471
14. Miyoshi H, Blömer U, Takahashi M et al (1998) Development of a self-inactivating lentivirus vector. J Virol 72:8150–8157
15. Zufferey R, Dull T, Mandel RJ et al (1998) Self-inactivating lentivirus vector for safe and effi cient in vivo gene delivery. J Virol 72: 9873–9880
16. Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4: 346–358
17. Cronin J, Zhang XY, Reiser J (2005) Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 5:387–398
18. Akkina RK, Walton RM, Chen ML et al (1996) High-effi ciency gene transfer into CD34+ cells with a human immunodefi ciency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol 70:2581–2585
19. Hanawa H, Kelly PF, Nathwani AC et al (2002) Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 5:242–251
20. Naldini L, Blömer U, Gallay P et al (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263–267
21. Naldini L, Blömer U, Gage FH et al (1996) Effi cient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 93:11382–11388
22. Blömer U, Naldini L, Kafri T et al (1997) Highly effi cient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 71:6641–6649
23. Mochizuki H, Schwartz JP, Tanaka K et al (1998) High-titer human immunodefi ciency virus type 1-based vector systems for gene delivery into nondividing cells. J Virol 72:8873–8883
24. Kordower JH, Bloch J, Ma SY et al (1999) Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol 160:1–16
25. Watson DJ, Kobinger GP, Passini MA et al (2002) Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol Ther 5:528–537
26. Cannon JR, Sew T, Montero L et al (2011) Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Exp Neurol 228:41–52
27. Gravel C, Götz R, Lorrain A et al (1997) Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons. Nat Med 3:765–770
28. Baumgartner BJ, Shine HD (1998) Permanent rescue of lesioned neonatal motoneurons and enhanced axonal regeneration by adenovirusmediated expression of glial cell-line-derived neurotrophic factor. J Neurosci Res 54: 766–777
29. Perrelet D, Ferri A, MacKenzie AE et al (2000) IAP family proteins delay motoneuron cell death in vivo. Eur J Neurosci 12:2059–2067
30. Sakamoto T, Kawazoe Y, Shen JS et al (2003) Adenoviral gene transfer of GDNF, BDNF and TGF beta 2, but not CNTF, cardiotrophin-1 or IGF1, protects injured adult motoneurons after facial nerve avulsion. J Neurosci Res 72:54–64
31. Barkats M, Horellou P, Colin P et al (2006) 1-methyl-4-phenylpyridinium neurotoxicity is attenuated by adenoviral gene transfer of human Cu/Zn superoxide dismutase. J Neurosci Res 83:233–242
32. Mazarakis ND, Azzouz M, Rohll JB et al (2001) Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 10: 2109–2121
33. Azzouz M, Ralph GS, Storkebaum E et al (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429:413–417
34. Wong LF, Azzouz M, Walmsley LE et al (2004) Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol Ther 9:101–111
35. Mentis GZ, Gravell M, Hamilton R et al (2006) Transduction of motor neurons and muscle fi bers by intramuscular injection of HIV-1-based vectors pseudotyped with select rabies virus glycoproteins. J Neurosci Methods 157:208–217
36. Kato S, Inoue K, Kobayashi K et al (2007) Effi cient gene transfer via retrograde transport in rodent and primate brains using a human immunodefi ciency virus type 1-based vector pseudotyped with rabies virus glycoprotein. Hum Gene Ther 18:1141–1151
37. Federici T, Kutner R, Zhang XY et al (2009) Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer. Genet Vaccines Ther 7:1
38. Kato S, Kobayashi K, Inoue K et al (2011) A lentiviral strategy for highly effi cient retrograde gene transfer by pseudotyping with fusion envelope glycoprotein. Hum Gene Ther 22:197–206
39. Kato S, Kuramochi M, Kobayashi K et al (2011) Selective neural pathway targeting reveals key roles of thalamostriatal projection in the control of visual discrimination. J Neurosci 31:17169–17179
40. Kato S, Kuramochi M, Takasumi K et al (2011) Neuron-specifi c gene transfer through retrograde transport of lentiviral vector pseudotyped with a novel type of fusion envelope glycoprotein. Hum Gene Ther 22:1511–1523
41. Kato S, Kobayashi K, Kuramochi M et al (2011) Highly effi cient retrograde gene transfer for genetic treatment of neurological diseases. In: Xu K (ed) Viral gene therapy, chapter 17. InTech, Rijeka, pp 371–380
42. Kato S, Kobayashi K, Inoue K et al (2013) Vectors for highly effi cient and neuron-specifi c retrograde gene transfer for gene therapy of neurological diseases. In: Molina FM (ed) Gene therapy—tools and potential applications, chapter 15. InTech, Rijeka, pp 387–398
43. Baekelandt V, Claeys A, Eggermont K et al (2002) Characterization of lentiviral vectormediated gene transfer in adult mouse brain. Hum Gene Ther 13:841–853
44. Duale H, Kasparov S, Paton JF et al (2004) Differences in transductional tropism of adenoviral and lentiviral vectors in the rat brainstem. Exp Physiol 90:71–78
45. Kitagawa R, Miyachi S, Hanawa H et al (2007) Differential characteristics of HIV-based versus SIV-based lentiviral vector systems: gene delivery to neurons and axonal transport of expressed gene. Neurosci Res 57:550–558
46. Englund U, Fricker-Gates RA, Lundberg C et al (2002) Transplantation of human neural progenitor cells into the neonatal rat brain: extensive migration and differentiation with long-distance axonal projections. Exp Neurol 173:1–21
47. Consiglio A, Gritti A, Dolcetta D et al (2004) Robust in vivo gene transfer into adult mammalian neural stem cells by lentiviral vectors. Proc Natl Acad Sci U S A 101:14835–14840
48. Geraerts M, Eggermont K, Hernandez-Acosta P et al (2006) Lentiviral vectors mediate effi - cient and stable gene transfer in adult neural stem cells in vivo. Hum Gene Ther 17: 635–650
49. Capowski EE, Schneider BL, Ebert AD et al (2007) Lentiviral vector-mediated genetic modifi cation of human neural progenitor cells for ex vivo gene therapy. J Neurosci Methods 163:338–349
50. Schlegel R, Tralka TS, Willingham MC et al (1983) Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site? Cell 32:639–646
51. Sinibaldi L, Goldoni P, Seganti L et al (1985) Gangliosides in early interactions between vesicular stomatitis virus and CER cells. Microbiologica 8:355–365
52. Mastromarino P, Conti C, Goldoni P et al (1987) Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH. J Gen Virol 68:2359–2369
53. Coil DA, Miller AD (2004) Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. J Virol 78:10920–10926
54. Bloor S, Maelfait J, Krumbach R et al (2010) Endoplasmic reticulum chaperone gp96 is essential for infection with vesicular stomatitis virus. Proc Natl Acad Sci U S A 107: 6970–6975
55. Kato S, Kobayashi K, Kobayashi K (2013) Dissecting circuit mechanisms by genetic manipulation of specifi c neural pathways. Rev Neurosci 24:1–8
56. De Palma M, Montini E, Santoni de Sio FR et al (2005) Promoter trapping reveals signifi - cant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105:2307–2315
57. Themis M, Waddington SN, Schmidt M et al (2005) Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther 12:763–771
58. Montini E, Cesana D, Schmidt M et al (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24:687–696
59. Prehaud C, Coulon P, LaFay F et al (1988) Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence. J Virol 62:1–7
60. Coulon P, Ternaux JP, Flamand A et al (1998) An avirulent mutant of rabies virus is unable to infect motoneurons in vivo and in vitro. J Virol 72:273–278
61. Superti F, Seganti L, Tsiang H et al (1986) Role of phospholipids in rhabdovirus attachment to CER cells. Brief report. Arch Virol 81:321–328
62. Hanham CA, Zhao F, Tignor GH (1993) Evidence from the anti-idiotypic network that the acetylcholine receptor is a rabies virus receptor. J Virol 67:530–542
63. Gastka M, Horvath J, Lentz TL (1996) Rabies virus binding to the nicotinic acetylcholine receptor α subunit demonstrated by virus overlay protein binding assay. J Gen Virol 77: 2437–2440
64. Thoulouze MI, Lafage M, Schachner M et al (1998) The neural cell adhesion molecule is a receptor for rabies virus. J Virol 72: 7181–7190
65. Tuffereau C, Bénéjean J, Blondel D et al (1998) Low-affi nity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus. EMBO J 17:7250–7259
66. Albertini AA, Baquero E, Ferlin A et al (2012) Molecular and cellular aspects of rhabdovirus entry. Viruses 4:117–139
67. Tuffereau C, Schmidt K, Langevin C et al (2007) The rabies virus glycoprotein receptor p75NTR is not essential for rabies virus infection. J Virol 81:13622–13630
68. Towne C, Schneider BL, Kieran D et al (2010) Effi cient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther 17: 141–146
69. Towne C, Setola V, Schneider BL et al (2011) Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefi t in fALS mice. Mol Ther 19:274–283
70. ElMallah MK, Falk DJ, Lane MA et al (2012) Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9. Hum Gene Ther Methods 23:148–156
71. Hirano M, Kato S, Kobayashi K et al (2013) Highly effi cient retrograde gene transfer into motor neurons by a lentiviral vector pseudotyped with fusion glycoprotein. PLoS One 8, e75896
72. Kato S, Kobayashi K, Kobayashi K (2014) Improved transduction effi ciency of a lentiviral vector for neuron-specifi c retrograde gene transfer by optimizing the junction of fusion envelope glycoprotein. J Neurosci Methods 227:151–158